Can-Fite BioPharma (CANF) Research & Development (2014 - 2023)

Can-Fite BioPharma (CANF) has 10 years of Research & Development data on file, last reported at -$1.3 million in Q4 2023.

• For the quarter ending Q4 2023, Research & Development fell 87.98% year-over-year to -$1.3 million; the trailing twelve-month figure through Dec 2023 stood at -$6.0 million (changed 0.0% YoY), and the FY2025 full-year result was -$6.7 million, down 16.26% from the prior year.
• Research & Development was -$1.3 million for Q4 2023 at Can-Fite BioPharma, up from -$1.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $1.4 million in Q1 2019 to a low of -$5.4 million in Q2 2019.
• A 5-year average of -$2.2 million and a median of -$2.0 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development slumped 115.51% in 2019 and soared 78.27% in 2022, its largest moves.
• Can-Fite BioPharma's Research & Development stood at -$4.0 million in 2019, then gained by 26.87% to -$2.9 million in 2020, then retreated by 7.08% to -$3.1 million in 2021, then jumped by 78.27% to -$674000.0 in 2022, then slumped by 87.98% to -$1.3 million in 2023.
• Per Business Quant data, the three most recent Research & Development figures were -$1.3 million in Q4 2023, -$1.3 million in Q3 2023, and -$1.4 million in Q2 2023.